AIM ImmunoTech (AIM) will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech announces follow-up clinical study of Ampligen with FluMist
- AIM ImmunoTech announces Safety Committee approval to proceed with Phase 2
- AIM ImmunoTech files to sell units, no amount given
- AIM ImmunoTech announces publication of clinical study results for AMP-518 trial
- AIM ImmunoTech highlights new article on links between COVID-19, ME/CFS